|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 321 | ALVAC-HIV (vCP205) + Oligomeric gp160MN/LAI-2 Prime-Boost in 91 HIV-Seronegative Adults: Summary of Safety and Immunogenicity Data
J. Kim*1, J. Cox2, S. Ratto-Kim2, T. VanCott2, N. Michael1, R. El Habib3, M. Klein3, B. Gilliam2, D. Birx1, J. McNeil1, and M. Robb1 1Walter Reed Army Inst. of Res., Washington, DC, USA; 2Henry M. Jackson Fndn., Rockville, MD, USA; and 3Aventis-Pasteur, Lyon, France |
| 322 | Cytotoxic T-Lymphocyte Responses in Volunteers Enrolled in a Phase I/II HIV-1 Prime-Boost Trial in Thailand
M. de Souza*1, C. Karnasuta1, J. Cox2, S. Gurunathan3, W. Heyward4, D. Birx2, J. Mc Neil2, A. Brown1, P. Pittisuttithum5, S. Nitayaphan1, and the TAVEG 6 1Armed Forces Res. Inst. of Med. Sci., Bangkok, Thailand; 2US Military Res. Program, Rockville, MD, USA; 3Aventis-Pasteur, Swiftwater, PA, USA; 4VaxGen, Inc., Brisbane, CA, USA; 5Vaccine Trial Ctr., Bangkok, Thailand; and 6Thai AIDS Vaccine Evaluation Group, Bangkok, Thailand |
| 323 | A Decade of HIV Vaccine Development in Thailand
J. G. McNeil for the US Army-Royal Thai Army HIV Res. Collaboration and the Thailand HIV/AIDS Vaccine Evaluation Group Walter Reed Army Inst. of Res., Rockville, Maryland, USA |
| 324 | HIV Risk Behavior Change in a Phase-III HIV Vaccine Efficacy Trial
B. Bartholow*1, S. Buchbinder2, D. McKirnan3, V. Goli1, C. Celum4, and the VaxGen Study Team5 1CDC, Atlanta, GA, USA; 2San Francisco Dept. of Publ. Hlth., CA, USA; 3Univ. of Illinois, Chicago, USA; 4Univ. of Washington, Seattle, USA; and 5VaxGen, Inc., Brisbane, CA, USA |